Compare Novo Nordisk A/S (NVO) vs Western Digital Corp (WDC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Western Digital Corp — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while Western Digital Corp trades at $397.28 (market cap $147.23B). The key difference: Novo Nordisk A/S and Western Digital Corp are close in size by market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Western Digital Corp for 37 Days on average.
| NVO | WDC | |
|---|---|---|
Market Cap | $165.31B | $147.23B |
Volume | 11,432,838 | 9,341,468 |
Sector | Health | Technology |
52-Week High | $63.98 | $746.23 |
52-Week Low | $35.29 | $113.13 |
Typical Hold Time | 116 Days | 37 Days |
Enterprise Value | $179.56B | $146.70B |
Dividend Yield | 4.71% | 0.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
Western Digital (WDC) trades at $393.31, down 2.94% amid concerns about increased competition from Toshiba's planned HDD production expansion. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and impressive profitability metrics including 71.97% net income margin and 131.02% ROE. Technical indicators signal bearish momentum with the price below key resistance levels, while analyst consensus remains overwhelmingly bullish with a $647.58 price target representing 65% upside potential.
WDC presents a compelling investment case with robust AI-driven storage demand and strong financial performance, though near-term headwinds from competitive pressures and technical weakness warrant caution. The company's dominant market position and margin expansion potential support long-term growth, but investors should monitor Toshiba's competitive moves and quarterly execution against elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Western Digital Corp
Western Digital is a vertically integrated supplier of data storage solutions, spanning both hard disk drives and solid-state drives. In the HDD market it forms a practical duopoly with Seagate, and it is the largest global producer of NAND flash chips for SSDs in a joint venture with competitor Kioxia.
Read more on WDC →
